Do you want to read an article? Please log in or register.
Outcomes of Concurrent Radiotherapy With Tarlatamab in Extensive-Stage Small Cell Lung Cancer From the DLL3 PanTUMOR Database
Lung Cancer
RECOMMENDED
Related content
Lung Cancer
Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)
Lung Cancer
Phillips WJ, Zhan LJ, Chowdhury D, Gill J, Sun A, Rittberg R, Cohen V, Gibson AJW, Yan M, Liwski D, Surapaneni S, D'Amours MF, Yu FPS, Kim Y, Qadeer RA, Dawe DE, Agulnik J, Navani V, Fung AS, Snow S, Kuruvilla S, Ho C, Lok BH, Liu G, Wheatley-Price P, Moore S
doi: 10.1016/j.lungcan.2025.108840
Lung Cancer
Real-World Clinical Outcomes of Concurrent Chemotherapy and Dose-Escalated Twice-Daily Radiotherapy With Simultaneous Integrated Boost (SIB) for Limited-Stage Small Cell Lung Cancer
Clin Lung Cancer
Celikarslan S, Sezen D, Duman M, Durankus NK, Oymak SE, Esen CSB, Rustamov A, Nasir A, Guclu SB, Kanıtez M, Kaban K, Yumuk F, Selcukbiricik F, Mandel NM, Cesur E, Erus S, Tanju S, Dilege S, Gumus T, Atasoy C, Demirkurek C, Falay O, Demirkol O, Bulutay P, Firat P, Atagun Y, Selek U
doi: 10.1016/j.cllc.2026.03.010
Lung Cancer
A Phase II Study of Accelerated Hyperfractionated Thoracic Radiotherapy With Dose Escalation to 54 Gy With Concurrent Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Long-Term Results at a Single Institution
Clin Lung Cancer
Matsuura K, Komaki R, Kono M, Kudo T, Ono A, Kameoka T, Shintani I, Kusaba H, Kawakubo A, Ando Y, Nishihara K, Iwamoto Y, Shoda H, Katsuta T, Kagemoto M
doi: 10.1016/j.cllc.2025.09.003
RECOMMENDED
Lung Cancer
Characterizing Risk Factors and Outcomes in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer Who Do Not Complete, or Who Experience Progression During/Within 42 Days of, Concurrent Chemoradiotherapy: The POSITION Study
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
Clin Lung Cancer
Mountzios G, Weng JK, Zairi E, Hsieh K, Chander P, Dunlop W, Qiao Y, Wang A, Januszewski A
doi: 10.1016/j.cllc.2026.01.005
Lung Cancer
Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States
Adv Ther
Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S
doi: 10.1007/s12325-025-03408-z
Lung Cancer
Validation of the lung immune prognostic index in extensive-stage small cell lung cancer: Post hoc analysis of the caspian and IMpower133 phase 3 trials
Eur J Cancer
Auclin E, Roulleaux Dugage M, Gorría T, Laguna JC, Anguita D, Montes A, Rota M, Ferriol-Galmes M, Vauchier C, Lavaud P, Besse B, Mezquita L
doi: 10.1016/j.ejca.2026.116955
RECOMMENDED
Lung Cancer
Chemoimmunotherapy Versus Chemotherapy for Extensive-Stage Small Cell Lung Cancer in the Real-World Setting: Retrospective Study of 904 Patients
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Dimitriou K, Shi S, Marginenau A, Blasi M, Bozorgmehr F, Klotz LV, Eichhorn F, Schneider MA, Allgäuer M, Shah R, Bischoff H, Weykamp F, Stenzinger A, Thomas M, Christopoulos P
doi: 10.1016/j.cllc.2026.06.004
RECOMMENDED
Lung Cancer
Real-world comparative effectiveness of atezolizumab versus durvalumab for extensive-stage small-cell lung cancer
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Aiba T, Hara S, Tominaga S, Yamamoto R, Sakashita H, Sakaguchi T, Ando Y, Koshio J, Takigami A, Maemondo M, Sugawara S
doi: 10.1016/j.lungcan.2026.109355
Lung Cancer
Tumor-Agnostic Circulating Tumor DNA Analysis as a Comprehensive Predictive Biomarker of Recurrence after Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer
Clin Lung Cancer
Nakamura M, Kageyama SI, Hirata H, Ohira M, Sakai SA, Hakozaki Y, Hojo H, Fujisawa T, Yamashita R, Haeno H, Kanai A, Suzuki Y, Yamaguchi M, Tsuchihara K, Zenda S
doi: 10.1016/j.cllc.2025.09.013